Showing 15 posts of 34 posts found.


LegoChem and Iksuda expand License Agreement for antibody drug conjugates

June 22, 2021
Manufacturing and Production ADC, License Agreement, deal, technology

Iksuda Therapeutics, a developer of antibody drug conjugates (ADCs), has announced the expansion of the research collaboration and License Agreement …

Exscientia buys Austrian cancer cell screening company for €50 million

June 17, 2021
AI, EU, deal, marketing, sales

UK-based AI pioneers Exscientia has announced the purchase of rival AI firm Allcyte for €50 million. The multimillion deal, paid …

Novo Holdings acquires BBI Group in £400 million deal

June 15, 2021
Manufacturing and Production acqusition, deal, finance

Novo Holdings, a holding company of the Novo Group, has acquired BBI Group from Exponent for an enterprise value of …


MSD partners up with Seattle Genetics in two oncology development deals potentially worth over $4bn

September 15, 2020
Manufacturing and Production, Sales and Marketing MSD, Seattle Genetics, deal, pharma

MSD has signed two new oncology-based deals with Seattle Genetics which together could be worth up to around $4.4 billion. …


Amgen drops $2.7bn to acquire stake in Chinese biotech in bid to expand in the region

November 1, 2019
Medical Communications, Research and Development, Sales and Marketing Amgen, BeiGene, Cancer, China, deal, oncology, pharma

Amgen has signed an agreement with Chinese biotech BeiGene to acquire a 20.5% stake in the latter, in a bid …


Gilead buys Novartis’ herpes, flu and cold virus preclinical programmes

July 23, 2019
Manufacturing and Production Gilead, Novartis, antivrial, deal, herpes, influenza, rhinovirus

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat …


Gilead invests $5.1 billion into Galapagos NV

July 15, 2019
Sales and Marketing Galapagos, Gilead, biotech, collaboration, deal, drug discovery, pharma

Gilead has entered into a 10 year partnership with Belgo-Dutch biotech Galapagos NV. The collaboration will see Gilead invest $5.1 …


MSD buys Peloton Therapeutics in deal worth $2.1 billion

May 22, 2019
Research and Development Cancer, MSD, acquisition, biotech, deal, oncology, pharma

MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion. US …


Takeda completes Shire acquisition

January 8, 2019
Manufacturing and Production M&A, MA, Shire, Takeda, acquisition, deal, pharma

Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm …


Taisho Pharma to buy Bristol-Myers Squibb’s consumer health business in deal worth $1.6 bn

December 19, 2018
Business Services BMS, Japan, M&A, MA, Taisho, deal

Japanese company Taisho Pharmaceuticals has offered Bristol-Myers Squibb $1.6 billion for its UPSA consumer health business. With more than a …

Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m

December 12, 2018
Research and Development Cancer, Oxford Biotherapeutics, WuXi Biologics, alliance, deal, oncology

Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology platform company WuXi Biologics, in …


Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment

November 16, 2018
Medical Communications Boehringer, Cancer, Epizyme, deal, oncology

German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, …

AstraZeneca sells off three drugs in deal worth $350 million

November 6, 2018
Manufacturing and Production AstraZeneca, asthma, covis, deal, royalties

Anglo-Swedish multinational AstraZeneca has agreed to sell the rights to three asthma and rhinitis drugs in a deal worth $350 …


J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn

November 6, 2018
Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea

Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal …


Roche signs $1 billion deal with cell therapy firm SQZ biotech

October 17, 2018
Research and Development Roche, SQZ, collaboration, deal, oncology

The Massachusetts-based cell therapy company SQZ Biotech, has announced the expansion of its collaboration with Swiss pharma giant Roche, in …

Latest content